Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2572)	9/2/2009 1:47:05 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MDCO is up for 3rd day on a roll and is closing its May 13 DG, the day it announced that it was canceling its PIII of Cangrelor,because results were not showing advantage over Plavix.<g> Today's volume is already above 5M > 8x its ADV, but below the 15,303,700 that traded on May 13.<g> bigcharts.marketwatch.com Today it announced that it had received a new patent for Angiomax, and on Monday it had announced the publication in Lancet of data showing that Angiomax reduced cardiac mortality and improved survival in a study involving 3000 patients with ST-elevation myocardial infarctions,compared with those that were treated with heparin plus a platelet glycoprotein inhibitor.(Both groups had been pre-treated with angioplasty.) But the stock still faces a good amount of resistance at the $10 level. MDCO has 4Qs of better revenues, but earnings have been lower in the last 3Qs and the EE for 2009 are around $0.30 vs. the $0.72 earned in 2008. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2572)	9/3/2009 10:04:42 AM
From: Jibacoa	Respond to of 3722

CRIS opened with a good UG and is trading above its Apr 2007 H of $4.35 <g> bigcharts.marketwatch.com Today it announced that two publications describing clinical data generated with GDC-0449 were published in the NEMJ One entitled “Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma,” provides an overview of the PI data for the 33 patients treated in this study. The other paper is a case study entitled “Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449,” which provides an overview of the treatment of a single adult medulloblastoma patient with GDC-0449. CRIS doesn't have significant LTD, but has been burning its cash at a good clip.<g> bigcharts.marketwatch.com Bernard